{"page":{"totalFilteredElements":347},"studies":[{"active":true,"description":"Jade - Klinische Forschungsplattform zur Behandlung und zum Ergebnis bei Patienten mit hepatozellul&#228;rem oder cholangiozellul&#228;rem Krebs<br />","eudractNumber":null,"id":6544,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04510740","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2020-08-31T12:11:49+02:00","shortTitle":"JADE - Registerplattform Leberkrebs","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors","eudractNumber":"2024-513285-19-00","id":10011,"indications":[{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"ras-Gen","id":"mt_28"},{"name":"NRAS","id":"mt_6"},{"name":"KRAS","id":"mt_7"},{"name":"HRAS","id":"mt_70"},{"name":"KRAS-G12C","id":"mt_250"}],"nctNumber":null,"phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2026-06-01T11:25:20+02:00","shortTitle":"KO-2806-001","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"},{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"A Phase III, Randomized, open-label study evaluating the efficacy and safety of Divarasib and Pembrolizumab versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in patients with previously untreated, KRAS G12C-mutated, advanced or metastatic non-squamous non&#8722;small cell lung cancer","eudractNumber":"2024-518365-10-00","id":11679,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"ras-Gen","id":"mt_28"},{"name":"KRAS","id":"mt_7"},{"name":"KRAS-G12C","id":"mt_250"}],"nctNumber":"NCT06793215","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-01-01T09:29:01+01:00","shortTitle":"KRAScendo 2","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"<div>A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy, in Subjects With Relapsed and/or Refractory B-cell Lymphoma</div>","eudractNumber":"2020-000562-41","id":7242,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04989803","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2023-01-01T08:43:59+01:00","shortTitle":"KT-US-499-0150","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"<div>Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells</div>","eudractNumber":"2020-005843-21","id":7303,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD19","id":"mt_55"}],"nctNumber":"NCT05041309","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2023-02-16T13:40:47+01:00","shortTitle":"KT-US-982-5968","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"}]},{"active":true,"description":"A FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, \nPHARMACOKINETICS AND PHARMACODYNAMICS OF KUP-101A \nIN PATIENTS WITH SELECTED ADVANCED SOLID TUMORS","eudractNumber":"2025-522402-21","id":11935,"indications":[{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"},{"id":"hau2","name":"Basaliom"},{"id":"hau3","name":"Spinaliom (Plattenepithelkarzinom)"},{"id":"hau4","name":"Merkelzellkarzinom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT03416335","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2026-06-01T13:01:11+02:00","shortTitle":"KUP-CT01","therapeutical":true,"therapyLines":[{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"AML-Register und Biomaterialdatenbank der Studienallianz Leuk&#228;mie (SAL) und der AML Cooperative Group (AML-CG)<br />","eudractNumber":null,"id":370,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2011-09-23T09:28:47+02:00","shortTitle":"Klinisches AML-Register (SAL, AML-CG)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"AML-Register und Biomaterialdatenbank der Studienallianz Leuk&#228;mie (SAL) und der AML Cooperative Group (AML-CG)","eudractNumber":null,"id":5759,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2019-04-29T11:05:37+02:00","shortTitle":"Klinisches AML-Register (SAL, AML-CG)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Analyse des Gesamt- und Tumorfreien &#220;berlebens von Patienten mit Kolonkarzinomen als indirekter Parameter der Chemotherapie-Effektivit&#228;t einer definierten Chemotherapie in Abh&#228;ngigkeit von der anatomischen Lokalisation des Prim&#228;rtumors im adjuvanten Ansatz.","eudractNumber":null,"id":8311,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2014-06-01T08:18:06+02:00","shortTitle":"Kolonsegment(Chemo)-Studie","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Molekulares Fingerprinting zur Krebserkennung<div><br /></div><div>DRKS00019844</div>","eudractNumber":null,"id":11557,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2026-06-15T10:02:55+02:00","shortTitle":"L4L","therapeutical":false,"therapyLines":[]}]}